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Prospects  for malaria  eradication  will  be greatly  enhanced  by  an  effective  vaccine,  but  parasite  genetic
diversity  poses  a major  impediment  to  malaria  vaccine  efﬁcacy.  In recent  pre-clinical  and  ﬁeld  trials,
vaccines  based  on  polymorphic  Plasmodium  falciparum  antigens  have  shown  efﬁcacy  only  against  homol-
ogous  strains,  raising  the  specter  of  allele-speciﬁc  immunity  such  as that  which  plagues  vaccines  against
inﬂuenza  and HIV.  The  most  advanced  malaria  vaccine,  RTS,S,  targets  relatively  conserved  epitopes  on
the  P. falciparum  circumsporozoite  protein.  After  more  than  40  years  of  development  and testing,  RTS,S,eterologous
llele-speciﬁc efﬁcacy
ross-protection
has  shown  signiﬁcant  but  modest  efﬁcacy  against  clinical  malaria  in  phase  2 and  3 trials.  Ongoing  phase
2  studies  of an  irradiated  sporozoite  vaccine  will ascertain  whether  the full protection  against  homolo-
gous  experimental  malaria  challenge  conferred  by  high  doses  of  a whole  organism  vaccine  can  provide
protection  against  diverse  strains  in  the  ﬁeld. Here  we  review  and  evaluate  approaches  being  taken  to
tectiv
ublisdesign broadly  cross-pro
©  2015  P
. Introduction
A malaria vaccine that prevents infection would reduce malaria
orbidity and mortality and accelerate malaria eradication efforts
1]. Leading approaches for achieving this goal include subunit vac-
ines that target sporozoites and blood stage parasites and that
lock transmission of gametocytes to mosquitoes, as well as whole
rganism vaccines intended to block sporozoite invasion of liver
ells, entirely preventing blood stage infection and gametocytoge-
esis [1,2].
The most advanced malaria vaccine, RTS,S/AS01, targets Plas-
odium falciparum circumsporozoite protein (CSP; expressed
n pre-erythrocytic stages) and moderately reduces the risk of
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clinical malaria (efﬁcacy 40–70% in different populations) but does
not entirely prevent infection in ﬁeld trials [3]. Subunit blood
stage vaccines have also had limited success in reducing clinical
malaria or parasitemia [4–7]. One such blood stage vaccine can-
didate, FMP2.1/AS01, based on the P. falciparum apical membrane
antigen 1 (AMA1), had no overall efﬁcacy against clinical malaria.
However, the FMP2.1/AS01 vaccine had signiﬁcant allele-speciﬁc
efﬁcacy against clinical malaria caused by parasites identical to
the vaccine strain with respect to speciﬁc amino acid positions
previously identiﬁed as important determinants of allele-speciﬁc
natural immunity in vitro [8], in ﬁeld trials [9] and in response to
vaccination with a monovalent vaccine [7,10].
Immunization with “Combination B” a vaccine (Table 1) based
on merozoite surface protein 2 (MSP2), MSP1 and ring-infected
erythrocyte surface antigen (RESA) had overall efﬁcacy in reduc-
ing parasitemia, but efﬁcacy was  restricted to infections with
vaccine-like alleles of MSP2 [4]. Thus both blood stage vaccines,
FMP2.1/AS01 and Combination B, selectively controlled the growth
in the blood of parasites with vaccine-type variants of the tar-
get antigens (Table 1). These efﬁcacy trials demonstrated that
strategies are needed to overcome extensive [11], sometimes
extreme [9], sequence diversity in vaccine antigen encoding genes
[12].
BY license (http://creativecommons.org/licenses/by/4.0/).
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Table  1
Malaria vaccines and allele-speciﬁc efﬁcacy.
Vaccine Antigen Stage Allele-speciﬁc efﬁcacy Reference
RTS,S Circumsporozoite protein (CSP) Pre-erythrocytic No [30]
AMA1-C1 Apical membrane antigen 1 (AMA1) Erythrocytic No [52]
FMP2.1/AS01 Apical membrane antigen 1 (AMA1) Erythrocytic Yes [7]
Combination B Merozoite surface protein 2 (MSP2), MSP1 Erythrocytic Yes [4]
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(Ring-infected erythrocyte surface antigen
(RESA)
SPf66 Merozoite surface protein 2 (MSP1) 
Surveys of vaccine antigen diversity in natural parasite popula-
ions have revealed regions of proteins under balancing selection
s immune targets and determined the frequency of different poly-
orphisms and haplotypes in different populations worldwide
13]. Meta-analyses combining all available data [9,14] and studies
f laboratory isolates from many different countries [15] have been
seful in cataloging global diversity and identifying the most com-
on  haplotypes circulating locally and worldwide. These studies
ave shown that antigen alleles can be sub-grouped on the basis of
equence similarity at codons for immunologically relevant amino
cids into a manageable number of subgroups [14–16]. However,
he link between these haplotype groupings and antigenic related-
ess has not been well established [17,18].
The antigen haplotypes (“strains”) included in all malaria vac-
ines currently in development were chosen based on available
aboratory isolates (“freezer epidemiology”), and in many cases
ave not taken into account haplotype prevalences at clinical trial
ites or in intended target populations. This may  explain the fail-
re of some malaria vaccines tested to date [12]. Measuring the
enetic and antigenic diversity of P. falciparum antigens may  facil-
tate the design of broadly cross-protective multi-strain malaria
accines that include relevant diverse alleles of antigens addressing
ll life cycle stages [16].
. Impact of vaccination on genetic diversity of
reakthrough infections
.1. Vaccine-induced selection in other pathogens
Antigenic selection, which is the accumulation of amino acids
hanges that render an antigen less recognizable by the immune
ystem, is seen during inﬂuenza virus seasonal monitoring. This
urveillance has identiﬁed novel strains that can successfully
nfect both vaccinated and unvaccinated hosts and that are there-
ore incorporated into the following year’s vaccine [19]. In other
athogens, selection may  occur more slowly. For example, a 10-
ear follow-up of the Hib vaccine [20] and a 4-year genetic
urveillance following the introduction of the meningococcal C
ig. 1. Effect of allele-speciﬁc efﬁcacy on breakthrough infections. The malaria vaccine con
s  infected by ﬁve different parasites with ﬁve variants (cyan, red, dark blue, yellow and
nd  cyan) and closely related variants (dark blue) are prevented (C). Heterologous variant
D,  E).Erythrocytic Yes [33]
vaccine in the United Kingdom [21] showed non-signiﬁcant
increases in genetic distance from the vaccine strain. These obser-
vations illustrate the capacity of microorganisms to adapt to
modiﬁed host environments.
A sieve analysis consists of measuring the allele-speciﬁc
immunological barrier to infection or disease [22]. Such a sieve
analysis of human immunodeﬁciency virus-1 (HIV-1) sequences
following immunization with the MRKAd5 vaccine showed a
greater distance between HIV vaccine recipients sequences com-
pared to those of the control group [23].
Vaccine-induced selection and/or antigenic drift (changes in
gene frequencies due to chance) following immunization may
reduce overall vaccine efﬁcacy in the long term [24] (Fig. 1). To mit-
igate this risk, molecular epidemiology studies are needed to assess
the baseline genetic diversity of vaccine candidate antigens (Fig. 2)
and the diversity and distribution of alleles following immunization
with polymorphic antigens. Moreover the antigenic variation of
vaccine candidate antigens should be assessed very early in vaccine
development (Fig. 2) to select alleles based on antigenic differences,
and not just genetic differences, as these may not fully overlap
[17,18].
2.2. Malaria vaccines
The P. falciparum genome consists of approximately 5400 genes
distributed over 14 chromosomes [25]. Almost 4% of the genes
encode proteins that are thought to be involved in immune eva-
sion and host parasite interactions [26]. At least 31% of the
predicted proteins have one or more transmembrane domains or
GPI anchored proteins, including several of the surface antigens
that have been tested in vaccine trials (e.g. AMA1, MSP2, CSP) [26].
These antigens are targets of humoral immunity, particularly dur-
ing malaria infection [4]. In endemic areas, an individual acquires
only partially protective immune responses following repeated
infections from multiple strains of the parasite, suggesting that the
immune response may  be allele-speciﬁc to some extent. This allele
speciﬁcity decreases with age, reﬂecting repeated exposure and the
broadening of the immune response [27].
tains two  variants (red and cyan) of a polymorphic antigen (A). When an individual
 green) of the same proteins (B), malaria clinical episodes with homologous (red
s (yellow and green) may increase within the individual and the whole population
7508 A. Ouattara et al. / Vaccine 3
Fig. 2. Screening procedure for the design of a broadly efﬁcacious subunit malaria
vaccine. The ﬁrst step of the selection process consists of using ﬁeld samples to
assess the baseline genetic diversity of vaccine candidate antigens. Selected antigen
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of laboratory strains [39]. The mechanism underlying this broad-andidates are then expressed and used to produce polyclonal antibodies. Following
his step, in vitro functional assays are conducted followed by a clinical trial in non-
uman primate for successful candidates.
.2.1. Pre-erythrocytic subunit vaccines
Previous data on malaria vaccine-induced selection are limited
y the small number of malaria vaccines that have reached phase
 trials. RTS,S/AS01, directed against highly conserved B-cell epi-
opes in the repeat region of the pre-erythrocytic antigen CSP, is
he vaccine candidate that has progressed the furthest in clinical
esting [3]. Initial studies of the allele-speciﬁc efﬁcacy of RTS,S in
hase 2 trials measured the difference in the frequency of individual
SP alleles in vaccinees compared to controls. Haplotype analyses
n these studies were restricted to Th2R and Th3R alleles encod-
ng T-cell epitopes, and did not examine the repeat region thought
o be the dominant target of protective antibodies [28,29], and no
election for parasites with non-vaccine strain CSP was  detected
30] (Table 1). While small sample sizes could have resulted in
issing relatively small selective effects in these initial studies,
rospective molecular epidemiological studies also suggest that
SP is not the target of naturally-acquired allele-speciﬁc immu-
ity directed at either the B-cell or T-cell epitopes [31]. However,
train-speciﬁc efﬁcacy was  seen in a much larger phase 3 trial of
TS,S in children at 11 African sites. RTS,S was better at protecting
gainst malaria caused by vaccine-type parasites in older children,
ut not in the youngest infants [32]. In older children, but not in
he youngest infants, various measures of efﬁcacy were approxi-
ately 10 to 15 percentage points lower when they were evaluated
gainst non–vaccine type parasites. This recent result supports the
dea that careful selection of vaccine strains and diversity-covering
pproaches may  help to improve the modest efﬁcacy of this leading
alaria vaccine [33].
.2.2. Whole organism vaccines
Another approach to overcome allele-speciﬁc immunity might
e to overwhelm the parasite by targeting not just one or a few but
housands of antigens with a whole parasite vaccine. In a recent
ontrolled Human Malaria Infection trial, an irradiated sporozoite-
ased vaccine induced full protection in all 6 recipients of the
ighest dose administered [34]. This experimental challenge trial
ested the PfSPZ Vaccine against homologous challenge with a par-
site clone very nearly identical to the vaccine strain. The results
f ongoing phase 2 studies in Mali and Tanzania will provide3 (2015) 7506–7512
preliminary measures of the efﬁcacy of this whole organism vaccine
against heterologous strains.
2.2.3. Blood-stage vaccines
The combination B malaria vaccine signiﬁcantly reduced para-
sitemia overall, but increased parasitemia with non-vaccine type
parasites (based on MSP2) in vaccinated individuals in a phase
2b trial in Papua New Guinea [4]. However, other vaccines based
on MSP1 (YSLFQKEKMVL) and other peptides (SPf66) [35] had
no effect on the allele frequencies of MSP1 sequences in vacci-
nees compared to controls (Table 1). No evidence of selection was
observed, although some evidence of decreased multiplicity of
infection (MOI) was observed in vaccinated participants indicat-
ing that the vaccine may  not have an allele-speciﬁc efﬁcacy effect.
If antigen selection is taking place following immunization with
a potential allele-speciﬁc vaccine, it may  reduce the overall efﬁ-
cacy of the vaccine. Indeed, the efﬁcacy of some vaccines against
other pathogens that are based on polymorphic antigens has been
attributed to the inclusion of diverse forms of the same antigen in
the formulation [36]. Therefore, an understanding of allele-speciﬁc
efﬁcacy is an important step in the development of a multivalent
broadly efﬁcacious malaria vaccine.
3. Designing cross-protective malaria vaccines
Vaccines for other polymorphic pathogens have been designed
to overcome genetic diversity by including diverse strains, e.g. inac-
tivated trivalent polio vaccine [37], or multiple variants of vaccine
antigens, e.g. multivalent pneumococcal vaccines [38]. As a ﬁrst
step toward a broadly efﬁcacious malaria vaccine, the antigenic
variants known to be most prevalent in the target populations, or,
as in the case of HPV, the most virulent strains should be those
selected to include in the vaccine. Malaria vaccines currently under
development have not been designed in this way. Instead, in part
because of a lack of molecular epidemiological information on hap-
lotype prevalence, conveniently available laboratory isolates have
been used to derive recombinant vaccine antigens. Recently, new
approaches have been taken by researchers to cover the diversity of
malaria vaccine candidates [39]. These approaches have been made
possible by recent progress in the understanding of parasite biol-
ogy, and advances in bioinformatics, genomics and the availability
of the parasite genome [40,41].
3.1. Diversity covering approaches
3.1.1. Immuno-dampening and bioinformatics approaches
Most decisions about which variant(s) of a polymorphic anti-
gen to include in a broadly efﬁcacious malaria vaccine have been
arbitrary. An unlucky choice may  result in a failed vaccine candi-
date, as likely occurred with the FMP1/AS02A MSP1 vaccine, which
includes a variant of the antigen that turned out to be relatively rare
in nature [6,11,42]. To optimize variant selection for vaccine design,
researchers have used different approaches to reduce the number
of strains to include in vaccine formulations. Rabbit immunization
experiments using a mixture of two  AMA1 variants (FVO and 3D7)
yielded functional antibody responses equal to the homologous
antigens at half the dose [43]. Responses to strains not covered by
either component (e.g. M24), however, were not broadened [43].
Immunization with a mixture of three AMA1 alleles designed to
cover amino acid diversity represented by 355 GenBank entries
yielded a broad functional antibody responses to a small panelened response was elucidated by comparing the epitope range of
rabbit polyclonal antibodies against a polyvalent and monovalent
AMA1 vaccine [44]. It was  found that in addition to responding
ccine 3
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o all variable epitopes, antibody responses following immuniza-
ion with a mixture of four natural AMA1 variants were refocused
oward conserved functional epitopes, a phenomenon termed epi-
ope dilution. Stochastic modeling of afﬁnity maturation using a
wo-epitope model of AMA1 further explained a mechanism for
pitope dilution [45]. After identifying amino acids that were bind-
ng residues of inhibitory antibodies [8], seven out of ten residues
n AMA1 cluster one loop, a highly polymorphic region of the
MA1 region that is the target of antibody-mediated inhibitory
ntibodies, were substituted with alanine. Contrary to the initial
ypothesis, the alanine-mutated protein failed to enhance cross-
eactive inhibitory activities [46]. A subsequent study used a more
onservative approach by mutating only ﬁve key polymorphic
esidues in AMA1 [47]. This approach broadened reactivity across
eterologous alleles, but at a cost of reduced overall invasion-
nhibitory activity.
In a follow-up study, a multivalent AMA1 vaccine was designed
ased on four strains (Quadvax) that are broadly representative of
ost laboratory strains [44]. In in vitro assays, Quadvax showed
otent inhibition against the four homologous strains in addition
o 22 non-vaccine laboratory and recent ﬁeld isolates [44]. Most
mportantly, this study showed that mixing only a limited num-
er of diverse strains can dilute the polymorphisms and divert
he immunogenicity toward conserved regions of the AMA1 pro-
eins. These ﬁndings suggest that it is possible to cover antigen
iversity by carefully selecting a subset of diverse strains. In a
imilar approach but using sequences generated from ﬁeld sam-
les and a Bayesian clustering algorithm that separated alleles into
roups based on genetic distance, it was possible to reduce the
umber of strains relevant for an AMA1-based vaccine to six [15].
 recent study suggested that a pentavalent AMA1 vaccine may
nduce protection against a very large number of malaria parasites
orldwide [48]. While mixing native allelic proteins has been the
ost successful way to overcome diversity of pathogens, the cost of
anufacturing such a complex multivalent vaccine against malaria
ay  be prohibitive.
It is worth noting that immuno-dampening, which consists of
utating highly polymorphic residues to reduce their immuno-
enicity [47], may  affect the three dimensional structure of the
rotein resulting in reduced immunogenicity [46] while grouping
aplotypes based on a very ﬁnite number of sequences may  results
n clusters that are not representative of the worldwide distribution
f variants as observed for AMA1 [9].
.1.2. Serological approaches
Since sequence differences and similarities may  not strongly
redict antigenic differences, it can be informative to select alle-
es or constructs for vaccines based on antigenic properties. This
s an established approach for vaccines against viral and bacterial
athogens. For example, antibodies against a panel of reference
trains are used to serotype infections in a population. For MSP2, it
s probably reasonable to group different polymorphic variants into
wo major serogroups or serotypes, which represent the two allelic
amilies. However, in the case of AMA1, classifying different vari-
nts into serogroups is more challenging. Importantly, emerging
ata suggest that antigenic diversity of AMA1 is more restricted
han would be expected from sequence analyses [18]. Analyses
f the speciﬁcity and cross-reactivity of functional anti-AMA1
ntibodies generated by immunization of experimental animals
gainst different isolates suggest that a vaccine comprised of three
o ﬁve different alleles may  be sufﬁcient to inhibit all isolates
18,39,40,48]. Complementary studies of naturally-acquired anti-
odies using multi-antigen competition ELISAs also suggested that
he inclusion of three or four different AMA1 alleles in a vaccine
ay  be sufﬁcient to cover antigenic diversity, provided the correct
lleles are selected [17]. This approach may  be helpful in selecting3 (2015) 7506–7512 7509
alleles for inclusion in a multi-allele vaccine. A prominent fea-
ture of naturally-acquired antibodies to AMA1 is that they target
highly polymorphic inhibitory epitopes [49]; therefore developing
strategies to refocus antibodies toward conserved or less poly-
morphic epitopes should reduce the propensity for immune
evasion.
3.1.3. Molecular epidemiology techniques
The use of ﬁeld data to select variants to include in multiva-
lent vaccines was pioneered by researchers working on inﬂuenza
and pneumococcal vaccines. From a septavalent vaccine in 2000,
the number of serotypes in the pneumococcal conjugate vac-
cine was increased to 13 in 2010 to cover the most relevant
serotypes identiﬁed in the ﬁeld [50]. The pneumococcal polysac-
charide vaccine covers 23 of the 90 capsular serotypes observed
worldwide [51]. A similar approach is being used by malaria vac-
cine developers in attempts to circumvent the genetic diversity
of vaccine antigens and improve the overall efﬁcacy of malaria
vaccine candidates [52,53]. These ﬁndings in addition to anti-
genic data were used to infer which haplotypes could be included
in cross-protective multivalent vaccines and to guide assessment
of allele-speciﬁc efﬁcacy in ﬁeld trials of two AMA1 vaccines
[7,10,54].
Polymorphisms responsible for immune escape may be far
apart on the linear sequence but cluster in three-dimensional
space (i.e. conformational epitopes) and therefore the deﬁnition
of antigenic diversity from genetic data is not straightforward.
Mapping polymorphisms to three-dimensional protein structures
can identify clustered residues that may  form conformational
epitopes [8]. Molecular epidemiological studies that track the
dynamics of polymorphism in natural populations and during
vaccine trials, and cross-sectional surveys which use population
genetics to deﬁne regions under selection and assess the frequency
of different polymorphisms and haplotypes, have been used
to pinpoint the speciﬁc polymorphic amino acids that mediate
immune escape [11,9,12]. Since alleles under balancing selection
tend to maintain moderate allele frequencies within and between
populations, strategies including focusing only on polymorphisms
present in a substantial proportion of isolates or those with similar
frequencies between populations have been used to predict impor-
tant polymorphisms [55,56]. Although these approaches have their
limitations, they can help to narrow the focus on speciﬁc regions
or polymorphism. Combined with serological approaches these
methods can help to predict key immune escape polymorphisms.
If done as part of the development of novel antigens as vaccine
candidates, this would help to deﬁne different serotypes and thus
advance the selection of appropriate alleles for inclusion in a
diversity-covering vaccine [16].
Experimental data suggesting that cross-protection against
diverse strains can be achieved [57] are encouraging, but in vitro
data do not necessarily predict cross-protective immune responses
in vaccinated humans. Antigen diversity is one reason why  in vitro
or animal results do not readily translate into efﬁcacious vaccines
in humans. An MSP1 vaccine that gave rise to human antibodies
that inhibited growth of three diverse P. falciparum isolates in vitro
[42] turned out not to protect against clinical malaria caused by
diverse parasites in the ﬁeld [6]. New subunit malaria vaccines
should therefore be designed based on comprehensive information
about antigenic diversity in natural parasite populations (Fig. 2).
While it might be feasible to design efﬁcacious multivalent vaccines
that target proteins with a manageable number of antigenically dis-
tinct forms, the notion of developing a broadly efﬁcacious vaccine
targeting an extremely polymorphic antigen may  be daunting. In
addition, there may  also be vaccine space limits for the total antigen
dose in a vaccine formulation.
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.1.4. Conserved target approaches
An ideal malaria vaccine might be based on conserved antigens
hat induced broadly efﬁcacious antibodies. Conserved antigens are
ften assumed to be less immunogenic than the highly polymor-
hic antigens used in ﬁrst generation malaria vaccine candidates,
ut malaria incidence studies and clinical trials suggest that con-
erved malaria antigens can induce strong and speciﬁc immune
esponses in animals [58] and humans [59]. One approach used
o reduce the effect of antigen diversity on vaccine efﬁcacy con-
ists of expressing fragments of vaccine antigens that are target of
onserved monoclonal antibodies. The challenge now is to identify
he three dimensional structure of relevant antigens to design and
xpress fragments that can structurally mimic  the conserved mAb
pitopes [60,61]. Peptides/proteins that are generated can be tested
y ELISA and/or ﬂow cytometry using sera collected in endemic
egions. Fragments that are antigenic and/or cross-reactive can be
rioritized as malaria vaccine candidates. This strategy was  applied
o identify a region of the gene encoding RH5 that is the target of
nhibitory antibodies [62]. Immunization of mice with virus-like
articles displaying the short sequence induced antibodies that
ad strong invasion inhibitory activities [44]. It remains to be seen
ow this epitope display approach for Rh5 would compare to the
ull-length vaccine. However, vaccines based on epitope display
pproaches in HIV have thus far failed to recapitulate the inhibitory
ctivity of the parent mAb  [63]. A recent non-human primate trial of
 RH5-based vaccine provides evidence that a protein with limited
olymorphism can induce protection against heterologous para-
ites [58].
The short fragment approach could be limited by the confor-
ation of fragments that are being expressed. Small peptides or
roteins fragments are expressed from synthetic genes that are
ostly linear. Therefore, the disulﬁde bonds that link amino acids
hat are not contiguous may  be missing resulting in proteins that
ay not retain important structural features. Such proteins in a
accine formulation may  not be efﬁcacious due to a lack of immuno-
enicity or the production of antibodies that are not speciﬁc to it
argeted malaria antigen.
. Whole proteome and parasite methods
.1. Protein microarrays
A protein microarray technology ﬁrst used to measure serore-
ctivity to thousands of proteins derived from the P. falciparum
eference genome [64] has been adapted to evaluate allele-speciﬁc
umoral immunity by printing dozens to hundreds of variants of
ntigens of interest on the array [27,65]. This diversity array was
robed with sera from adult and children from malaria transmis-
ion areas during consecutive malaria infections and/or clinical
pisodes to assess the dynamics of malaria immune responses.
his new tool holds potential to help identify variants that are
mmunogenic, as well as those that are cross protective. The vari-
nts identiﬁed through this process could be used as components
f a multivalent sub-unit malaria vaccine.
Another new approach is offered by an ultra-dense array com-
rised of short oligomers with near complete amino acid overlap
f all antigens printed on the array, with the capacity to screen sera
gainst 2.1 million peptides, covering essentially entire microbial
roteomes [66]. In addition to evaluating antigen immunogenicity,
he technique identiﬁes residues that are antibody binding sites. A
ossible limitation of the peptide arrays is that short linear pep-
ides may  not emulate the native protein structure, resulting in
on-speciﬁc binding of antibodies. Other approaches using more
argeted arrays of puriﬁed and validated proteins, often full length,
ave identiﬁed new lead antigens that could be considered in vac-
ine development [67,68].3 (2015) 7506–7512
4.2. Whole parasite approaches
The successful immunization of birds and monkeys with killed
whole malaria parasites in the early 20th century [69–72] was
followed in the mid-1970s by experimental challenge using
mosquitoes to immunize humans with metabolically active,
radiation-attenuated sporozoites [73,74]. Although sterile pro-
tection against challenge was achieved, the concept was  judged
impractical until recently when advances in parasite cultivation
methods and mosquito breeding have resulted in the develop-
ment of a whole sporozoite malaria vaccine [75]. Recently, in a
Controlled Human Malaria Infection (CHMI) study to test the efﬁ-
cacy of a whole irradiated sporozoite malaria vaccine, subjects
receiving high doses of the vaccine were fully protected against
subsequent homologous experimental malaria infection [32]. This
success has raised hopes for a highly efﬁcacious malaria vaccine
in the near future. Very limited data from human heterologous
challenge studies provide some evidence for both cross-strain
and even cross-species protection [76]. However, the possibility
that diversity-covering approaches such as a multi-strain vaccine
may  be required for whole organism vaccines is supported by a
recent in vitro study of the allele-speciﬁc efﬁcacy of Plasmodium
yoelii yoelii. Under a controlled-infection and treatment procedure,
immunity to pre-erythrocyte antigens was speciﬁc to the strains
used during infection [77]. An identical study [78] using Plasmod-
ium chabaudi sporozoites likewise found that the immunity against
the pre-erythrocytic stage of the parasite life cycle was allele-
speciﬁc.
Ongoing or planned phase 2 trials in endemic settings in Mali,
Tanzania and Burkina Faso will ascertain whether this whole organ-
ism vaccine provides strain-transcending immunity. These ﬁeld
trials will also provide an opportunity to perform a genome-wide
sieve analysis to identify genetic loci under selection by the vac-
cine, although larger studies may  be required to achieve the sample
size necessary to detect evidence of selection in genome-wide
sieve analyses. Such analyses may  provide invaluable informa-
tion not only about how to select strains for a broadly efﬁcacious
multi-strain whole organism vaccine, but also about what speciﬁc
polymorphic antigens contribute to allele-speciﬁc immunity to P.
falciparum.
5. Discussion and perspectives
Pathogen populations characterized by polymorphic surface
antigens appear to have evolved in response to immune selection
by the human host by expressing polymorphic surface antigens
that retain function despite signiﬁcant cross-strain variation [79]. A
leading method used by vaccine developers for other microorgan-
isms is to cover antigenic diversity by selecting clinically relevant
strains that are representative of the distribution of the microor-
ganism in their vaccine design. Salk [37] methodically classiﬁed
circulating polio strains prior to the selection of one the three
strains that he would use in the inactivated polio vaccine. Moreover,
the conjugate 13-valent and the 23-valent polysaccharide pneu-
mococcal vaccines have been designed to overcome the genetic
diversity of 90 serotypes that are distributed worldwide. How-
ever, malaria parasites are much more complex with scores of
surface proteins with extensive diversity that is not well under-
stood. Furthermore, commonly used reference strains are quite
often found infrequently in naturally circulating parasite popula-
tions. The “freezer epidemiology” approach of selecting available
and convenient strains for the design of a malaria vaccine has there-
fore shown it limitations. The design of a broadly efﬁcacious malaria
vaccine should take into account the baseline genetic and antigenic
diversity (Fig. 1) of candidate antigens [10,16,12]. This approach
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reverse vaccinology) [80], which uses a combination of bioinfor-
atics analyses to select antigens and molecular epidemiology to
elect the most prevalent allele/strain in the ﬁeld, offers a promis-
ng approach for designing a broadly efﬁcacious malaria vaccine.
n addition to all these approaches, the design of chimeric proteins
s a strategy that is being used to improve malaria vaccine efﬁcacy
81].
. Concluding remarks
Almost all ﬁrst generation malaria vaccines were designed
ithout consideration of antigen variant prevalences in the ﬁeld.
olecular epidemiology, genomic epidemiology, serological, and
onserved peptide approaches in addition to immuno-dampening
ave each been used to guide the selection of relevant variants.
hese approaches are all limited by relying essentially on the linear
equences for analysis. Moreover, while it may  be feasible to design
ultivalent vaccines based on few variants, designing vaccines that
nclude more than 10 variants will require tremendous techni-
al advances. However, a multivalent malaria vaccine may  offer
edundancies that compensate for failure of individual component
ntigens to induce functional antibodies. Whole-organism malaria
accines, whether based on a single strain or multiple strains, may
vercome antigenic diversity by offering even greater redundancy.
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